Prostate Cancer Detection Using Urine Glycoproteins Overview In a recent study, researchers investigated the potential of using pre-digital rectal examination (DRE) urine specimens to detect aggressive prostate cancer (AG-PCa) by comparing glycoproteins found in pre- and post-DRE urine samples. The study involved 154 pre-DRE urine specimens from individuals with no cancer at
Tag: cancer
lung cancer patients and pulmonary embolism risk factors
lung cancer patients and pulmonary embolism risk factors Overview Pulmonary embolism (PE) is a grave complication observed in individuals afflicted with lung cancer. This investigation aimed to ascertain the risk factors and evaluate the clinical attributes of advanced lung cancer patients who develop PE. In this research, a retrospective assessment was conducted on
PD-1/L1 Inhibitors: Treatment Efficacy In Urothelial Carcinoma
PD-1/L1 Inhibitors: Treatment Efficacy In Urothelial Carcinoma Overview Programmed cell death‐1/ligand 1 (PD-1/PD-L1) inhibitors represent a novel therapeutic approach for advanced urothelial carcinoma, prompting the need for a comparative assessment of their effectiveness and safety in comparison to traditional chemotherapy. To address this, a comprehensive meta-analysis of randomized controlled trials conducted until
Encapsulated Papillary Carcinoma Membrane Characteristics
Encapsulated Papillary Carcinoma Membrane Characteristics Overview This study focused on encapsulated papillary carcinoma (EPC), a type of breast carcinoma characterized by a thick fibrous capsule-like structure surrounding the tumor, often interpreted as a thickened basement membrane (BM). The primary objective was to investigate the geometric properties of the EPC capsule and determine
Ibrutinib Treatment In Waldenström Macroglobulinemia
Ibrutinib Treatment In Waldenström Macroglobulinemia Waldenström macroglobulinemia (WM) is a rare type of non-hogdkins lymphoma driven by the gene mutation MYD88L265P. Ibrutinib, the first approved treatment, is effective but can cause side effects. A study found that 27% of WM patients needed to reduce Ibrutinib doses due to side effects like
Stomach Cancer: A Meta-Analysis Of Robotic Surgery Complications
Stomach Cancer: A Meta-Analysis Of Robotic Surgery Complications Gastric or stomach cancer prevalence varies significantly around the world, with higher rates in Asia, Africa, South America, and Eastern Europe. However, in the United States, stomach cancer is a growing concern due to its increased occurrence in the elderly population and its
Chemotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma
Chemotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma Overview This study aimed to investigate serious chemotherapy-induced thrombocytopenia (CIT) in nasopharyngeal carcinoma (NPC), focusing on its incidence, consequences, and predictors. The retrospective analysis of NPC patients from 2013 to 2015 revealed a 5.21% incidence of serious chemotherapy-induced thrombocytopenia. Patients experiencing severe thrombocytopenia had notably worse long-term prognoses,
Postoperative Delirium In The NICU: Hormonal Risk Factors
Postoperative Delirium In The NICU: Hormonal Risk Factors In neurosurgery, pituitary adenoma ranks as the second most common brain tumor. Recent advances in endoscope-assisted transsphenoidal surgery have revolutionized tumor resection, reducing complications. However, postoperative complications, particularly endocrine-related issues, remain critical in neurosurgical intensive care units (NICUs). Notably, postoperative delirium, intricately linked
Cancer Care: Gender Bias In Decision-Making
Cancer Care: Gender Bias In Decision-Making Overview In the realm of cancer care, the integration and execution of shared decision-making within clinical practice guidelines (CPGs) and consensus statements could potentially exhibit gender-based disparities. This study aimed to meticulously analyze recommendations pertaining to shared decision-making within CPGs and consensus statements, specifically focusing on
Non-Hodgkin Lymphoma Survivors: Secondary Malignancy Risk
Non-Hodgkin Lymphoma Survivors: Secondary Malignancy Risk The number of non-Hodgkin lymphoma (NHL) cases is rising, with an estimated 81,560 new diagnoses in the US in 2021. As survival rates improve, more NHL survivors face potential late effects, including secondary malignancies (SM) linked to treatments like chemotherapy and radiation. This research revisits
